undamentalytics Newsletter
Sign in

Recursion Pharmaceuticals, Inc. cash flow statement

In fiscal 2025, Recursion Pharmaceuticals, Inc.'s operations generated −$372m of cash; it spent $6.5m on capital projects, leaving free cash flow of −$378m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash from operations−57−45−159−84−288−359−372−311
Depreciation and amortisation2481224368474
Stock-based pay141528548211188
Capital spending464037121462
Free cash flow−61−51−198−121−300−373−378−312
Free cash flow after stock pay−62−56−213−148−353−455−490−401
Shares issued—0463144128300529219

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: CYTK vs RXRXABCL vs RXRXRXRX vs WVERXRX vs VRDN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Recursion Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Recursion Pharmaceuticals, Inc.